罗欣药业(002793.SZ)：预计前三季度净利润2270万元—2520万元 同比扭亏为盈

Core Viewpoint - Luoxin Pharmaceutical (002793.SZ) expects a net profit attributable to shareholders of 22.7 million to 25.2 million yuan for the first three quarters, marking a turnaround from losses year-on-year, with a net profit excluding non-recurring gains and losses of 4.7 million to 5.9 million yuan, also indicating a year-on-year turnaround [1] Group 1: Product Development - The commercialization process of the core innovative drug, Tegoprazan Tablets, has deepened, with the commercial team making significant progress in market expansion and access [1] - The product's terminal coverage in target markets has continuously expanded, leading to a significant year-on-year increase in sales, which has become a key driver of performance growth [1] Group 2: Financial Management - During the reporting period, the company has continuously optimized its working capital management [1] - The organization of special collection efforts for receivables has effectively improved the company's operating cash flow while reducing bad debt losses [1]